Abstract： Objective To study the effect of lizhuweisanlian combined with Killing Hp capsules on patients with chronic gastropathy and the effect of remedy treatment with PPI triple therapy and Killing Hp capsules on refractory patients. Methods 139 patients under initial treatment were divided into two groups at random. The study group (A) was given lizhuweisanlian and Killing Hp capsules for seven days while the control group (B) was given lizhuweisanlian for seven days. 121 patients for retreatment were divided into treatment group (group of supplement A, including A1, A2 and A3) and control group (group of supplement B). Group of supplement A1 was given Lizhuweisanlian and Killing Hp capsules for 14 days, group of supplement A2 was given PPI triple sequential therapy plus Killing Hp capsules, and group of supplement A3 was given PPI triple therapy for 10 days. Results The eradication rate of helicobacter pylori in initial treatment group was 90.60% in group A and 83.33% in group B，P＞0.05. The total incidence rate of adverse effects including nausea, poor appetite, abdominal discomfort and skin rash was lower in group A than in group B （2.08% vs 10%），P＞0.05. In remedy treatment patients, the eradication rate of helicobacter pylori was 63.33% in group A1 and 60.00% in group B，P＞0.05. The effective rate in A2 and A3 was over 80%, group A2 （P<0.01），group A3 （P>0.05）. As for such adverse effects as nausea, poor appetite and abdominal discomfort, there was significant difference between group A and group B(3.33% vs 20.00%），P＜0.05. The total incidence rate of adverse effects was lower in group A1 than in group B （6.67% vs 43.33%)，P＜0.01. Conclusions Lizhuweisanlian, especially PPI triple therapeutic scheme combined with Killing Hp capsules, has good synergism and can increase the effect of killing Helicobacter pylori while reducing adverse effects.
2012, Vol. 23 
